224 related articles for article (PubMed ID: 11772257)
41. Phosphodiesterase 4 inhibitors: antiinflammatory therapy for chronic obstructive pulmonary disease at last?
Kerstjens HA; Timens W
Am J Respir Crit Care Med; 2003 Oct; 168(8):914-5. PubMed ID: 14555456
[No Abstract] [Full Text] [Related]
42. Cilomilast: pharmacokinetic and pharmacodynamic interactions with digoxin.
Zussman BD; Kelly J; Murdoch RD; Clark DJ; Mbchb ; Schubert C; Collie H
Clin Ther; 2001 Jun; 23(6):921-31. PubMed ID: 11440291
[TBL] [Abstract][Full Text] [Related]
43. Effects of ciclamilast, a new PDE 4 PDE4 inhibitor, on airway hyperresponsiveness, PDE4D expression and airway inflammation in a murine model of asthma.
Deng YM; Xie QM; Tang HF; Sun JG; Deng JF; Chen JQ; Yang SY
Eur J Pharmacol; 2006 Oct; 547(1-3):125-35. PubMed ID: 16956605
[TBL] [Abstract][Full Text] [Related]
44. Phosphodiesterase 4 inhibition of beta2-integrin adhesion caused by leukotriene B4 and TNF-alpha in human neutrophils.
Meliton AY; Muñoz NM; Lambertino A; Boetticher E; Learoyd J; Zhu X; Leff AR
Eur Respir J; 2006 Nov; 28(5):920-8. PubMed ID: 16807266
[TBL] [Abstract][Full Text] [Related]
45. [Phosphosdiesterase 4 inhibitors in the treatment of pulmonary diseases].
Xia XD; Dai YR; Xu ZJ
Zhonghua Jie He He Hu Xi Za Zhi; 2004 Jan; 27(1):57-9. PubMed ID: 14989829
[No Abstract] [Full Text] [Related]
46. Phosphodiesterase 4 inhibitors modulate beta2-adrenoceptor agonist-induced human airway hyperresponsiveness.
Faisy C; Risse PA; Naline E; Guerot E; Fagon JY; Devillier P; Advenier C
Life Sci; 2006 Oct; 79(20):1929-35. PubMed ID: 16820175
[TBL] [Abstract][Full Text] [Related]
47. Phosphodiesterase 4 inhibitors for the treatment of COPD.
Sturton G; Fitzgerald M
Chest; 2002 May; 121(5 Suppl):192S-196S. PubMed ID: 12010850
[TBL] [Abstract][Full Text] [Related]
48. Phosphodiesterase 4 inhibitor cilomilast inhibits fibroblast-mediated collagen gel degradation induced by tumor necrosis factor-alpha and neutrophil elastase.
Kohyama T; Liu X; Zhu YK; Wen FQ; Wang HJ; Fang Q; Kobayashi T; Rennard SI
Am J Respir Cell Mol Biol; 2002 Oct; 27(4):487-94. PubMed ID: 12356583
[TBL] [Abstract][Full Text] [Related]
49. Modulation of matrix metalloproteinase production from human lung fibroblasts by type 4 phosphodiesterase inhibitors.
Martin-Chouly CA; Astier A; Jacob C; Pruniaux MP; Bertrand C; Lagente V
Life Sci; 2004 Jul; 75(7):823-40. PubMed ID: 15183075
[TBL] [Abstract][Full Text] [Related]
50. Cyclic AMP-specific phosphodiesterase 4 inhibitors promote ABCA1 expression and cholesterol efflux.
Lin G; Bornfeldt KE
Biochem Biophys Res Commun; 2002 Jan; 290(2):663-9. PubMed ID: 11785950
[TBL] [Abstract][Full Text] [Related]
51. CGH2466, a combined adenosine receptor antagonist, p38 mitogen-activated protein kinase and phosphodiesterase type 4 inhibitor with potent in vitro and in vivo anti-inflammatory activities.
Trifilieff A; Keller TH; Press NJ; Howe T; Gedeck P; Beer D; Walker C
Br J Pharmacol; 2005 Apr; 144(7):1002-10. PubMed ID: 15685201
[TBL] [Abstract][Full Text] [Related]
52. L-454,560, a potent and selective PDE4 inhibitor with in vivo efficacy in animal models of asthma and cognition.
Huang Z; Dias R; Jones T; Liu S; Styhler A; Claveau D; Otu F; Ng K; Laliberte F; Zhang L; Goetghebeur P; Abraham WM; Macdonald D; Dubé D; Gallant M; Lacombe P; Girard Y; Young RN; Turner MJ; Nicholson DW; Mancini JA
Biochem Pharmacol; 2007 Jun; 73(12):1971-81. PubMed ID: 17428447
[TBL] [Abstract][Full Text] [Related]
53. Phosphodiesterase 4 inhibitors, structurally unrelated to rolipram, as promising agents for the treatment of asthma and other pathologies.
Dal Piaz V; Giovannoni MP
Eur J Med Chem; 2000 May; 35(5):463-80. PubMed ID: 10889326
[TBL] [Abstract][Full Text] [Related]
54. Anti-inflammatory potential of the selective phosphodiesterase 4 inhibitor N-(3,5-dichloro-pyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl]-glyoxylic acid amide (AWD 12-281), in human cell preparations.
Draheim R; Egerland U; Rundfeldt C
J Pharmacol Exp Ther; 2004 Feb; 308(2):555-63. PubMed ID: 14610230
[TBL] [Abstract][Full Text] [Related]
55. Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis.
Bäumer W; Hoppmann J; Rundfeldt C; Kietzmann M
Inflamm Allergy Drug Targets; 2007 Mar; 6(1):17-26. PubMed ID: 17352685
[TBL] [Abstract][Full Text] [Related]
56. Effect of PDE4 inhibitors on zymosan-induced IL-8 release from human neutrophils: synergism with prostanoids and salbutamol.
Au BT; Teixeira MM; Collins PD; Williams TJ
Br J Pharmacol; 1998 Mar; 123(6):1260-6. PubMed ID: 9559913
[TBL] [Abstract][Full Text] [Related]
57. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro.
Hatzelmann A; Schudt C
J Pharmacol Exp Ther; 2001 Apr; 297(1):267-79. PubMed ID: 11259554
[TBL] [Abstract][Full Text] [Related]
58. Pharmacological profile of a novel phosphodiesterase 4 inhibitor, 4-(8-benzo[1,2,5]oxadiazol-5-yl-[1,7]naphthyridin-6-yl)-benzoic acid (NVP-ABE171), a 1,7-naphthyridine derivative, with anti-inflammatory activities.
Trifilieff A; Wyss D; Walker C; Mazzoni L; Hersperger R
J Pharmacol Exp Ther; 2002 Apr; 301(1):241-8. PubMed ID: 11907180
[TBL] [Abstract][Full Text] [Related]
59. Lack of pharmacokinetic interactions between cilomilast and theophylline or smoking in healthy volunteers.
Murdoch RD; Zussman B; Schofield JP; Webber DM
J Clin Pharmacol; 2004 Sep; 44(9):1046-53. PubMed ID: 15317832
[TBL] [Abstract][Full Text] [Related]
60. Are phosphodiesterase 4 inhibitors just more theophylline?
Boswell-Smith V; Cazzola M; Page CP
J Allergy Clin Immunol; 2006 Jun; 117(6):1237-43. PubMed ID: 16750981
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
